NR1H4 and metabolic dysfunction-associated steatotic liver disease: The non-steroid structure of AT-II, along with its ability to activate FXR and alleviate ER stress in hepatocytes, promote us to investigate whether AT-II can effectively treat NAFLD by modulating the interplay between FXR and ER stress signaling pathways.